Galectin Therapeutics Inc. (NASDAQ:GALT – Get Rating) Director Richard A. Jr. Zordani bought 5,000 shares of the business’s stock in a transaction on Thursday, July 28th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $12,500.00. Following the completion of the transaction, the director now owns 29,583 shares in the company, valued at approximately $73,957.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Galectin Therapeutics Price Performance
NASDAQ GALT opened at $2.26 on Monday. The business has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $1.67. Galectin Therapeutics Inc. has a 52-week low of $1.19 and a 52-week high of $4.24. The company has a debt-to-equity ratio of 79.37, a quick ratio of 3.51 and a current ratio of 3.51. The stock has a market cap of $134.22 million, a price-to-earnings ratio of -3.90 and a beta of 1.55.
Galectin Therapeutics (NASDAQ:GALT – Get Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). Analysts anticipate that Galectin Therapeutics Inc. will post -0.75 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Institutional Trading of Galectin Therapeutics
Large investors have recently bought and sold shares of the business. Atria Wealth Solutions Inc. bought a new stake in Galectin Therapeutics during the 1st quarter worth approximately $460,000. State Street Corp grew its stake in shares of Galectin Therapeutics by 9.4% during the 1st quarter. State Street Corp now owns 173,740 shares of the company’s stock worth $280,000 after acquiring an additional 14,981 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Galectin Therapeutics by 21.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 56,184 shares of the company’s stock worth $90,000 after acquiring an additional 10,000 shares in the last quarter. Centaurus Financial Inc. bought a new position in shares of Galectin Therapeutics during the 1st quarter worth approximately $34,000. Finally, Commonwealth Equity Services LLC grew its stake in shares of Galectin Therapeutics by 42.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 38,220 shares of the company’s stock worth $50,000 after acquiring an additional 11,318 shares in the last quarter. 12.35% of the stock is owned by institutional investors.
About Galectin Therapeutics
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.